THERAPY DOSSIER · th-40dae22da147

BDNF-loaded cationic nanobubbles conjugated with MAP-2 antibody, destroyed by low-intensity focused ultrasound

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29360450 ↗2018Reported benefit

Noninvasive, targeted gene therapy for acute spinal cord injury using LIFU-mediated BDNF-loaded cationic nanobubble destruction.

RatSpinal cord injuryUnspecifiedSprague-DawleyMaleUltrasound-targeted delivery to the injured spinal cordApplied after acute spinal cord injury

Model: Acute spinal cord injury in rats

Low-intensity focused ultrasound mediated delivery increased BDNF expression, attenuated histological injury, reduced neuronal loss and apoptosis and improved BBB scores.

Extraction: extract · Supplied extraction confidence: 0.62. Machine-extracted fields require source verification.

Loading the evidence…